¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"group III fiber"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • axial fiber
    ̈ȏ
  • A-delta fiber
    Aµ¨Å¸½Å°æ¼¶À¯
  • adrenergic fiber
    ¾Æµå·¹³¯¸°¼¶À¯
  • afferent fiber
    µé½Å°æ¼¶À¯, ±¸½É½Å°æ¼¶À¯
  • afferent nerve fiber
    µé½Å°æ¼¶À¯, ±¸½É½Å°æ¼¶À¯
  • alveolar fiber
    ÀÌÆ²¼¶À¯
  • bag fiber
    ÇÙÁָӴϼ¶À¯, ÇÙÁָӴϱÙÀ°¼¼Æ÷
  • C fiber
    C¼¶À¯
  • circular fiber
    µ¹¸²¼¶À¯
  • climbing fiber
    ¿À¸§¼¶À¯
  • collagen fiber
    ¾Æ±³¼¶À¯
  • collagenous fiber
    ¾Æ±³¼¶À¯, Äݶó°Õ¼¶À¯
  • collateral fiber
    °ç¼¶À¯
  • connective tissue fiber
    °áÇÕÁ¶Á÷¼¶À¯
  • contractile fiber cell
    ¼öÃ༶À¯¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • nonionic polar group
    ºñÀ̿±ؼº±â
  • open group
    °ø°³Áý´Ü, °³¹æÁý´Ü
  • osmophore group
    ¹ßÇâ´Ü
  • prosthetic group
    ¹èÇÕ±º
  • self-help group
    ÀÚÁ¶Áý´Ü
  • soluble group
    °¡¿ëÇØ±º
  • symmetry group
    ´ëαº
  • taxonomic group
    ºÐ·ùÁý´Ü
  • topological group
    À§»ó±º
  • zymophore group
    È¿¼ÒÀÛ¿ëÁ·
  • prosthetic group-labeled immunoassay
    º¸Á¶±ºÇ¥Áö¸é¿ªºÐ¼®(¹ý)
  • Rh blood group system
    ¾Ë¿¡ÃëÇ÷¾×Çü±º
  • A-delta fiber
    ¿¡À̵¨Å¸½Å°æ¼¶À¯
  • adrenergic fiber
    ¾Æµå·¹³¯¸°¼¶À¯
  • afferent fiber
    (¢¡afferent nerve fiber) µé½Å°æ¼¶À¯
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • pilomotor fiber
    ¸ð(¹ß)¿îµ¿¼¶À¯(¡­ê¡ÔÑ àéë«).
  • postganglionic fiber
    ½Å°æÀýÀÌÈļ¶À¯, (½Å°æ)ÀýÈļ¶À¯(¡­àéë«).
  • postganglionic nerve fiber
    ½Å°æÀýÀÌÈĽŰ漶À¯
  • predentinal fiber
    Dz»ó¾ÆÁú¼¶À¯
  • preganglionic fiber
    ½Å°æÀýÀÌÀü¼¶À¯, (½Å°æ)ÀýÀü¼¶À¯(¡­àéë«).
  • preganglionic nerve fiber
    ½Å°æÀýÀÌÀü½Å°æ¼¶À¯
  • pressor fiber
    ½Â¾Ð¼¶À¯(¡­àéë«).
  • presynaptic fiber
    ½Ã³³½ºÀü¼¶À¯(¡­àéë«).
  • primary lens fiber
    ÀÏÂ÷¼öÁ¤Ã¼¼¶À¯(ìéó­â©ïÜô÷àéë«).
  • principal fiber
    À¸¶ä¼¶À¯
  • process of odontoblast [tomes fiber]
    »ó¾ÆÁú¸ð¼¼Æ÷µ¹±â
  • purkinje fiber
    ½ÉÀåÀüµµ±ÙÀ°¼¶À¯
  • radial fiber
    ºÎä»ì¼¶À¯, ¹æ»ç¼¶À¯(Û¯ÞÒ àéë«).
  • radial fiber
    ºÎê»ì½Å°æ¼¶À¯
  • radial fiber
    ºÎä»ì¼¶À¯, ¹æ»ç¼¶À¯(Û¯ÞÒ àéë«).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • control group
    ´ëÁ¶±º(ËÀ̡˴).
  • determinant group
    °áÁ¤±º(¡­ÏØ).
  • diagnosis related group(DRG)
    Áø´Ü¸íº° ±º, À¯»çÇÑ Áø´Ü¸íµé³¢¸® ¹­¾î À̸¦ ´ÜÀ§·Î ÀÇ·áºñ¸¦ ÁöºÒÇÏ´Â ¹æ¹ý
  • diagnostic related group
    Áø´Ü°ü·Ã±º
  • didactic group therapy
    ±³À°Àû Áý´Ü¿ä¹ý
  • directive group therapy
    Áö½Ã¼º Áý´Ü¿ä¹ý
  • discrepancy in ABO blood group
    ABO Ç÷¾×ÇüºÒÀÏÄ¡
  • end group
    ¸»´Ü±â.
  • enteric group
    Àå°è¼¼±Õ±º, Àå³»¼¼±Õ±º
  • evocative group therapy
    Ç¥ÇöÀû Áý´Ü¿ä¹ý(øúúÞîÜó¢Ó¥ÖûÛö)
  • frontal group of aphasia
    ÀüµÎ¿±½Ç¾î±º(¡­ã÷åÞÏØ).
  • functional group
    ÀÛ¿ë±â(íÂéÄÐñ).
  • glucophore group
    ´ã´ç±â.
  • green or yellow vegetable group
    ³ìȲ»öä¼Ò·ù.
  • group
    ±º
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Perivascular nerve fiber
    Ç÷°üÁÖÀ§½Å°æ¼¶À¯
    [¿¾ ¿ë¾î] Ç÷°üÁÖÀ§½Å°æ¼¶À¯
  • Efferent nerve fiber
    ³¯½Å°æ¼¶À¯
    [¿¾ ¿ë¾î] ¼öÃâ½Å°æ¼¶À¯
  • White muscle fiber
    ¹é»ö±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] ¹é¼¶À¯
  • Lens fiber
    ¼öÁ¤Ã¼¼¶À¯
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼¼¶À¯
  • Nerve fiber
    ½Å°æ¼¶À¯
    [¿¾ ¿ë¾î] ½Å°æ¼¶À¯
  • Conducting fiber
    ½ÉÀåÀüµµ±ÙÀ°¼¶À¯
    [¿¾ ¿ë¾î] Àüµµ°è±Ù¼¶À¯
  • Purkinje fiber
    ½ÉÀåÀüµµ±ÙÀ°¼¶À¯
    [¿¾ ¿ë¾î] ½ÉÀåÀÚ±ØÀüµµ¼¶À¯
  • Purkinje fiber
    ½ÉÀåÀüµµ±ÙÀ°¼¶À¯
    [¿¾ ¿ë¾î] Ǫ¸£Å²¿¹Àüµµ±Ù¼¶À¯
  • Red muscle fiber
    Àû»ö±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] Àû¼¶À¯
  • Dense fiber
    Ä¡¹Ð¼¶À¯
    [¿¾ ¿ë¾î] Á¶¹Ð¼¶À¯
  • Dense fiber
    Ä¡¹Ð¼¶À¯
    [¿¾ ¿ë¾î] Ä¡¹Ð¼¶À¯
  • Tendon fiber
    ÈûÁÙ¼¶À¯
    [¿¾ ¿ë¾î] °Ç¼¶À¯
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • guanidino group
    ±¸¾Æ´Ïµð³ë±â(Ðñ)
  • guanido group
    ±¸¾Æ´Ïµµ±â(Ðñ)
  • haptenic group
    ÇÕÅÙ±â(Ðñ)
  • high-mobility group
    °íÀ̵¿µµ ±º(ÍÔì¹ÔÑÓøÏØ)
  • hydroxyl group
    ÇÏÀ̵å·Ï½Ç±â(Ðñ)
  • hydroxymethyl group
    ÇÏÀ̵å·Ï½Ã¸ÞÆ¿±â(Ðñ)
  • hypsochromic group
    û»öÀ̵¿±â(ôìßäì¹ÔÑÐñ)
  • imidazole group
    À̴̹ÙÁ¹±â(Ðñ)
  • imino group
    À̹̳ë±â(Ðñ)
  • Inv group
    Inv ±º(ÏØ)
  • ketone group
    ÄÉÅæ±â(Ðñ)
  • labile methyl group
    ºÒ¾ÈÁ¤(ÝÕäÌïÒ)¸ÞÆ¿±â(Ðñ)
  • labile phosphate group
    ºÒ¾ÈÁ¤Àλê±â(ÝÕäÌïÒ×ò߫Ѩ)
  • leaving group
    ÀÌÅ»±â(×î÷­Ðñ)
  • linkage group
    ¿¬°ü±º(Ö¤Î¼ÏØ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
CIN 3, CIN III cervical intraepithelial neoplasia, grade 3 (severe dysplasia and carcinoma in situ)
CONPA-DRI III conpa-dri I plus intensified doxorubicin
DSM-III-R Diagnostic and Statistical Manual of Mental Disorders [of APA], third edition, revised
III Roman numeral three
III-para tertipara
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
HTLV-III Human T-cell leukaemia virus type III
HTLV-III Human T-lymphotropic virus type III
III CS III connecting segment
JH III Juvenile hormone III
pol III Polymerase III
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • C-fiber nociceptor
    C ¼¶À¯ Ä§ÇØ ¼ö¿ëü, C ¼¶À¯ À¯ÇØ ¼ö¿ë±â
  • calcified collagen fiber
    ¼®È¸È­ ±³¿ø ¼¶À¯
  • chain fiber
    ¿¬¼â ¼¶À¯
  • cholinergic postganglionic fiber
    Äݸ°¼º ÀýÈÄ ¼¶À¯
  • ciliocapsular fiber
    ¸ð¾çü ¼öÁ¤Ã¼ ³¶ ¼¶À¯
  • cochlear fiber
    ¿Í¿ì ½Å°æ
    ³»ÀÌ ½Å°æ °¡¿îµ¥ û°¢À» ÀüÇÏ´Â Áö°¢ ½Å°æ ¼¶À¯ÀÇ ´Ù¹ßÀ» ¿Í¿ì½Å°æ ¶Ç´Â û½Å°æÀ̶ó ÇÑ´Ù. ÃøµÎ°ñ¿¡ ±â¿ï¾îÁ®ÀÖ´Â ¿Í¿ìÀÇ °ñÃà¼Ó¿¡¼­ ³ª¼± ½Å°æÀýÀ» ¸¸µé¾î ¿Í¿ìÀÇ ³ª¼±±â¿¡ ºÐÆ÷Çϰí û°¢À» °üÀåÇÑ´Ù.
  • collagen fiber
    ±³¿ø ¼¶À¯
  • collagen fiber web
    ±³¿ø ¼¶À¯ ±×¹°
  • connective tissue fiber
    °áÇÕ Á¶Á÷ ¼¶À¯
  • elastic fiber
    ź·Â ¼¶À¯
    ¿¤¶ó½ºÆ¾À̶ó´Â ´Ü¹éÁú·Î µÇ¾î Àִµ¥, ¿¤¶ó½ºÆ¾Àº ¼¶À¯ ¸ð¾çÀ̳ª ÃþÆÇ ¸ð¾çÀ¸·Î Á¸ÀçÇÏ¸ç µ¿¸Æ º®, ź·Â Àδë, ¼¼±â°üÁö, ÇǺÎ, ź·Â ¿¬°ñ µîÀÇ ÁÖµÈ ±¸¼º ¿ä¼Ò°¡ µÈ´Ù.
  • fast fiber
    ¼Ó¼¶À¯
  • fast-twitch fiber muscle
    ½Å¼Ó ¿¬Ãà±Ù ¼¶À¯
  • FGP : functionally generated pathÀÇ ¾àÀÚ.

    fiber

    ¼¶À¯
    ±æ°í ½Ç°°Àº ±¸Á¶³ª À§ Àå°ü È¿¼Ò¿¡ ÀÇÇØ ¼ÒÈ­µÇÁö ¾ÊÀº À½½Ä¹°ÀÇ ±¸¼º ¼ººÐ.
  • fiber distributed data interface
    ±¤ ³×Æ®¿öÅ©
  • fiber optic
    ±¤¼¶À¯
    ÀÚ½ÅÀÇ ±æÀÌ ¹æÇâÀ¸·Î ºûÀ̳ª ¹æ»ç ¿¡³ÊÁöÀÇ Àü´ÞÀÌ °¡´ÉÇÑ Åõ¸íÇÑ ¼¶À¯°¡´Ú ȤÀº ´Ù¹ß
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
type III familial hyperlipoproteinaemia Hyperlipoproteinaemia characterised by increased plasma levels of LDL, beta-lipoproteins, pre-beta-lipoproteins, cholesterol, phospholipids, and triglycerides; hypertriglyceridemia induced by a high carbohydrate diet, and glucose tolerance is abnormal; frequent eruptive xanthomas and atheromatosis, particularly coronary artery disease; biochemical defect lies in apolipoproteins; there are many varieties.
Synonym: carbohydrate-induced hyperlipaemia, dysbetalipoproteinaemia, familial hyperbetalipoproteinaemia and hyperprebetalipoproteinaemia, familial hypercholesterolaemia with hyperlipaemia.
(05 Mar 2000)
type III hyperlipoproteinaemia <biochemistry> An inherited disorder (gene defect) where both cholesterol and triglycerides are elevated in the same patient. This condition accelerates the effects of atherosclerosis and thus increases the risk of cardiovascular disease. Conditions such as hypothyroidism, obesity and diabetes enhances this risk.
Origin: Gr. Haima = blood
(27 Sep 1997)
type III hypersensitivity reaction An immunologic category of diseases evoked by the deposition of antigen-antibody or antigen-antibody-complement complexes on cell surfaces, with subsequent involvement of breakdown products of complement, platelets, and polymorphonuclear leukocytes, and development of vasculitis; nephritis is common. Arthus phenomenon and serum sickness are classic examples, but many other disorders, including most of the connective tissue disease's, may belong in this immunologic category; immune complex disease's can also occur during a variety of disease's of known aetiology, such as subacute bacterial endocarditis.
See: autoimmune disease.
Synonym: immune complex disorder, type III hypersensitivity reaction.
(05 Mar 2000)
type III mucopolysaccharidosis <syndrome> An error of the mucopolysaccharide metabolism, with excretion of large amounts of heparan sulfate in the urine and severe mental retardation with hepatomegaly; skeleton may be normal or may present mild changes similar to those in Hurler's syndrome; several different types (A, B, C, and D) have been identified according to the enzyme deficiency; autosomal recessive inheritance.
Synonym: type III mucopolysaccharidosis.
(05 Mar 2000)
exonuclease III An exonuclease enzyme which removes nucleotides one at a time from the 5'-end of duplex DNA which does not have a phosphorylated 3'-end.
(09 Oct 1997)
factor III In the clotting of blood, tissue factor or thromboplastin; it initiates the extrinsic pathway by reacting with factor VII and calcium to form factor VIIa.
See: thromboplastin.
(05 Mar 2000)
uroporphyrin-III C-methyltransferase <enzyme> From pseudomonas denitrificans; enzyme of the cobalamin biosynthetic pathway which catalyses the c methylation of uroporphyrinogen III; also catalyses both nad+ dependent oxidation of precorrin-2 to sirohydrochlorin and insertion of iron into it to produce siroheme; cysg gene is from E coli; product of coba gene of pseudomonas; do not confuse with coba gene product of salmonella typhimurium which yields ATP-corrinoid adenosyltransferase
Registry number: EC 2.1.1.107
Synonym: uroiii methyltransferase, uroporphyrinogen III methylase, sumt methyltransferase, s-adenosylmethionine-uroporphyrinogen III methyltransferase, cysg gene product, siroheme synthase, coba gene product, propionibacterium
(26 Jun 1999)
uroporphyrinogen-III synthase <enzyme> An enzyme that catalyses the cyclization of hydroxymethylbilane to yield uroporphyrinogen III and water.
Chemical name: Hydroxymethylbilane hydro-lyase (cyclizing)
Registry number: EC 4.2.1.75
(12 Dec 1998)
forms of DNA i, II and III Refers to circular DNA removed from viruses and as plasmids. Form I is the DNA in its normal, supercoiled form. Form II is the DNA after one of the two strands has been nicked (cut apart), and is circular. Form III is the DNA after both strands have been broken, and is linear.
(09 Oct 1997)
Le Fort III craniofacial dysjunction A complex fracture in which the facial bones are separated from the cranial bones.
Synonym: Le Fort III craniofacial dysjunction, Le Fort III fracture, transverse facial fracture.
(05 Mar 2000)
Le Fort III fracture A complex fracture in which the facial bones are separated from the cranial bones.
Synonym: Le Fort III craniofacial dysjunction, Le Fort III fracture, transverse facial fracture.
(05 Mar 2000)
ABO blood group <haematology> The major human blood type system which describes the oligosaccharide glycoprotein antigens found on the surface of human blood cells.
According to the type of antigen present, a person may be assigned a blood type of A, B, AB or O. A second type of antigen, the Rh factor, renders a positive or negative blood type. The ABO blood group system is important because it determines who can donate blood to or accept blood from whom.
Type A or AB blood will cause an immune reaction in people with type B blood and type B and AB blood will cause a reaction in people with type A blood.
Conversely, type O blood has no A or B antigens, so people with type O blood are universal donors.
And since AB blood already produces both antigens, people who are type AB can accept any of the other blood types without suffering an immune reaction.
(04 Jul 1999)
actinobacteria group A group of gram-positive, heterogeneous bacteria. This group encompasses a range of morphologically, physiologically, and chemically different organisms and includes bacteria that form cocci, short rods, irregular rods, and mycelia that fragment.
(12 Dec 1998)
alkyl group <chemistry> A funtional group on an organic molecule which is derived from an alkane which has lost a hydrogen atom.
(13 Nov 1997)
aluminum group Aluminum, boron, gallium, indium, and thallium.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • minority group
    ¼Ò¼ö¹ÎÁ·(Çѳª¶óÀÇ)
  • peer group
    µ¿·á Áý´Ü;µ¿¹è Áý´Ü
  • pressure group
    ¾Ð·Â ´Üü
  • primary group
    Á¦ ÀÏÂ÷ Áý´Ü(°¡Á¤,Ä£±¸ µî)
  • rape group
    ÅäÀÇ(Åä·Ð)±×·ì
  • reference group
    ÁذŠÁý´Ü(°³ÀÎÀÌ ÀÚ±â ŵµ.ÆÇ´ÜÀÇ ±âÁØÀ¸·Î ¿©±â´Â ƯÁ¤ Áý´Ü)
  • splinter group
    ºÐÆÄ;¼Ò¼öÆÄ
  • tail group
    TAIL UNIT
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á